基于磷脂、胆固醇、粘菌素和壳聚糖的杂化纳米颗粒(HNPs)的开发、表征和抗菌评价,以对抗多重耐药革兰氏阴性菌。

IF 5.5 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pharmaceutics Pub Date : 2025-02-01 DOI:10.3390/pharmaceutics17020182
Isabella Perdomo, Carolina Mora, Juan Pinillos, José Oñate-Garzón, Constain H Salamanca
{"title":"基于磷脂、胆固醇、粘菌素和壳聚糖的杂化纳米颗粒(HNPs)的开发、表征和抗菌评价,以对抗多重耐药革兰氏阴性菌。","authors":"Isabella Perdomo, Carolina Mora, Juan Pinillos, José Oñate-Garzón, Constain H Salamanca","doi":"10.3390/pharmaceutics17020182","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Colistin, a lipopeptide antibiotic usually used as a last resort against multidrug-resistant bacterial strains, has also begun to address the challenge of antimicrobial resistance. <b>Objective</b>: this study evaluates whether hybrid nanoparticles (HNPs) composed of Phospholipon<sup>®</sup> 90G, cholesterol, and colistin can enhance its effectiveness against resistant clinical isolates of <i>Klebsiella pneumoniae</i>, a clinically significant Gram-negative bacterium. <b>Methods:</b> HNPs were developed using the ethanol injection method and coated with chitosan through a layer-by-layer technique. HNP characterization included measurements of particle size, polydispersity index (PDI), and zeta potential, along with thermal (DSC) and spectrophotometric (FT-IR) analyses. Ultrafiltration and ATR-FTIR were employed to assess colistin's association and release efficiencies. The biological evaluation followed CLSI guidelines. <b>Results:</b> uncoated hybrid nanoparticles (U-HNP) and chitosan-coated hybrid nanoparticles (Ch-HNP) described monodisperse populations, with respective PDI values of ~0.124 and ~0.150, Z-averages of ~249 nm and ~250 nm, and zeta potential values of +17 mV and +20 mV. Colistin's association and release efficiencies were approximately 79% and 10%, respectively. Regarding antimicrobial activity, results showed that colistin as part of HNPs is poorly effective against this microorganism. However, in the most resistant strain, colistin activity increased slightly when the HNP was coated with chitosan. <b>Conclusions:</b> HNPs described high stability against disaggregation, limiting the colistin release and, therefore, affecting antimicrobial performance.</p>","PeriodicalId":19894,"journal":{"name":"Pharmaceutics","volume":"17 2","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859251/pdf/","citationCount":"0","resultStr":"{\"title\":\"Development, Characterization, and Antimicrobial Evaluation of Hybrid Nanoparticles (HNPs) Based on Phospholipids, Cholesterol, Colistin, and Chitosan Against Multidrug-Resistant Gram-Negative Bacteria.\",\"authors\":\"Isabella Perdomo, Carolina Mora, Juan Pinillos, José Oñate-Garzón, Constain H Salamanca\",\"doi\":\"10.3390/pharmaceutics17020182\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Colistin, a lipopeptide antibiotic usually used as a last resort against multidrug-resistant bacterial strains, has also begun to address the challenge of antimicrobial resistance. <b>Objective</b>: this study evaluates whether hybrid nanoparticles (HNPs) composed of Phospholipon<sup>®</sup> 90G, cholesterol, and colistin can enhance its effectiveness against resistant clinical isolates of <i>Klebsiella pneumoniae</i>, a clinically significant Gram-negative bacterium. <b>Methods:</b> HNPs were developed using the ethanol injection method and coated with chitosan through a layer-by-layer technique. HNP characterization included measurements of particle size, polydispersity index (PDI), and zeta potential, along with thermal (DSC) and spectrophotometric (FT-IR) analyses. Ultrafiltration and ATR-FTIR were employed to assess colistin's association and release efficiencies. The biological evaluation followed CLSI guidelines. <b>Results:</b> uncoated hybrid nanoparticles (U-HNP) and chitosan-coated hybrid nanoparticles (Ch-HNP) described monodisperse populations, with respective PDI values of ~0.124 and ~0.150, Z-averages of ~249 nm and ~250 nm, and zeta potential values of +17 mV and +20 mV. Colistin's association and release efficiencies were approximately 79% and 10%, respectively. Regarding antimicrobial activity, results showed that colistin as part of HNPs is poorly effective against this microorganism. However, in the most resistant strain, colistin activity increased slightly when the HNP was coated with chitosan. <b>Conclusions:</b> HNPs described high stability against disaggregation, limiting the colistin release and, therefore, affecting antimicrobial performance.</p>\",\"PeriodicalId\":19894,\"journal\":{\"name\":\"Pharmaceutics\",\"volume\":\"17 2\",\"pages\":\"\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859251/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/pharmaceutics17020182\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/pharmaceutics17020182","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:粘菌素是一种脂肽类抗生素,通常作为抗多药耐药菌株的最后手段,也开始解决抗菌素耐药性的挑战。目的:本研究评估由磷脂®90G、胆固醇和粘菌素组成的混合纳米颗粒(HNPs)是否能增强其对临床耐药肺炎克雷伯菌(一种临床重要的革兰氏阴性菌)的有效性。方法:采用乙醇注射法制备HNPs,经壳聚糖层层包被制备。HNP表征包括粒径、多分散性指数(PDI)和zeta电位的测量,以及热(DSC)和分光光度(FT-IR)分析。采用超滤和ATR-FTIR评价粘菌素的结合和释放效率。生物学评价遵循CLSI指南。结果:未包覆的混合纳米粒子(U-HNP)和壳聚糖包覆的混合纳米粒子(Ch-HNP)呈现单分散种群,PDI分别为~0.124和~0.150,z -平均为~249 nm和~250 nm, zeta电位值为+17 mV和+20 mV。粘菌素的结合和释放效率分别约为79%和10%。在抗菌活性方面,结果表明粘菌素作为HNPs的一部分对该微生物的抗菌效果较差。然而,在最具抗性的菌株中,壳聚糖包被HNP后,粘菌素活性略有增加。结论:HNPs具有较高的抗分解稳定性,限制了粘菌素的释放,从而影响了抗菌性能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Development, Characterization, and Antimicrobial Evaluation of Hybrid Nanoparticles (HNPs) Based on Phospholipids, Cholesterol, Colistin, and Chitosan Against Multidrug-Resistant Gram-Negative Bacteria.

Background: Colistin, a lipopeptide antibiotic usually used as a last resort against multidrug-resistant bacterial strains, has also begun to address the challenge of antimicrobial resistance. Objective: this study evaluates whether hybrid nanoparticles (HNPs) composed of Phospholipon® 90G, cholesterol, and colistin can enhance its effectiveness against resistant clinical isolates of Klebsiella pneumoniae, a clinically significant Gram-negative bacterium. Methods: HNPs were developed using the ethanol injection method and coated with chitosan through a layer-by-layer technique. HNP characterization included measurements of particle size, polydispersity index (PDI), and zeta potential, along with thermal (DSC) and spectrophotometric (FT-IR) analyses. Ultrafiltration and ATR-FTIR were employed to assess colistin's association and release efficiencies. The biological evaluation followed CLSI guidelines. Results: uncoated hybrid nanoparticles (U-HNP) and chitosan-coated hybrid nanoparticles (Ch-HNP) described monodisperse populations, with respective PDI values of ~0.124 and ~0.150, Z-averages of ~249 nm and ~250 nm, and zeta potential values of +17 mV and +20 mV. Colistin's association and release efficiencies were approximately 79% and 10%, respectively. Regarding antimicrobial activity, results showed that colistin as part of HNPs is poorly effective against this microorganism. However, in the most resistant strain, colistin activity increased slightly when the HNP was coated with chitosan. Conclusions: HNPs described high stability against disaggregation, limiting the colistin release and, therefore, affecting antimicrobial performance.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmaceutics
Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.90
自引率
11.10%
发文量
2379
审稿时长
16.41 days
期刊介绍: Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications,  and short notes. Covered topics include pharmacokinetics, toxicokinetics, pharmacodynamics, pharmacogenetics and pharmacogenomics, and pharmaceutical formulation. Our aim is to encourage scientists to publish their experimental and theoretical details in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
期刊最新文献
Expanding the Gene Expression Profiling of Drug Transporters and Drug-Metabolizing Enzymes to Include the Upper Female Reproductive Tract. Pharmacokinetic and Pharmacodynamic Assessments of the Ivermectin and Levamisole Combination to Control Resistant Nematodes in Cattle. Carbon Dots in Nanomedicine: Advanced Fabrication, Biomedical Applications, and Future Clinical Perspectives. Crosslinking-Dependent Design of Hyaluronic Acid Matrices for Enhanced Bioadhesion and Cellular Response. Mucoadhesive Chitosan-Gellan Gum Nanoparticles for Rifampicin Delivery: Taguchi Optimization and In Vitro Release Behavior.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1